FDA review of GSK Lamictal XR prompts broader probe of historical control trials
10 March 2011
Donna Young
Please Login to read the full article.
10 March 2011
Donna Young
donna.young@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Eisai's novel anti-epileptic perampanel moves forward in Europe
- Comparator issue strikes again; Germany's IQWiG in doubt over GSK's Trobalt
- EMA to review label extension for Eisai's Zonegran as epilepsy monotherapy
- FDA highlights risk of impaired cognitive development in children exposed in utero to valproate products
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
